Coverage
Filings
Novo Nordisk said Wednesday it plans to cut approximately 9,000 jobs globally as part of a major restructuring aimed at refocusing on its core diabetes and obesity drug businesses amid slowing growth.
Novo Nordisk said Friday its popular weight-loss drug Wegovy has been approved by the U.S. Food and Drug Administration to treat a common type of liver disease, further expanding the blockbuster drug's market.
Novo Nordisk said Thursday it will advance both injectable and oral versions of its experimental obesity drug, amycretin, into late-stage Phase 3 clinical trials.
| 18 Feb 2003 |
| Novo Nordisk, current statement of shareholdings from 10 February 2003 | 10 Feb 2003 |
| Novo Nordisk, preliminary announcement of annual report 2002 | 6 Feb 2003 |
| Novo Nordisk, status re Novo Nordisk’s holding of its own shares (treasury shares) | 7 Jan 2003 |
| Novo Nordisk, Novo Nordisk acquires remaining shares in Biobrás | 19 Nov 2002 |